Comparative Immunogenicity of the Recombinant Receptor-Binding Domain of Protein S SARS-CoV-2 Obtained in Prokaryotic and Mammalian Expression Systems

Comparative Immunogenicity of the Recombinant Receptor-Binding Domain of Protein S SARS-CoV-2 Obtained in Prokaryotic and Mammalian Expression Systems

The receptor-binding domain (RBD) of the protein S SARS-CoV-2 is considered to be one of the appealing targets for developing a vaccine against COVID-19. The choice of an expression system is essential when developing subunit vaccines, as it ensures the effective synthesis of the correctly folded ta...

Full description

Bibliographic Details
Main Authors: Iuliia A. Merkuleva, Dmitry N. Shcherbakov, Mariya B. Borgoyakova, Daniil V. Shanshin, Andrey P. Rudometov, Larisa I. Karpenko, Svetlana V. Belenkaya, Anastasiya A. Isaeva, Valentina S. Nesmeyanova, Elena I. Kazachinskaia, Ekaterina A. Volosnikova, Tatiana I. Esina, Anna V. Zaykovskaya, Oleg V. Pyankov, Sophia S. Borisevich, Arseniya A. Shelemba, Anton N. Chikaev, Alexander A. Ilyichev
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Vaccines
Subjects:
SARS-CoV-2
COVID-19
subunit vaccines
S protein
receptor-binding domain
Online Access:https://www.mdpi.com/2076-393X/10/1/96

Internet

https://www.mdpi.com/2076-393X/10/1/96

Similar Items